Raymond James Financial
AQST icon

Raymond James Financial’s Aquestive Therapeutics AQST Stock Holding History

Raymond James Financial’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Sell
49,988
-5,234
-9% -$22K ﹤0.01% 5031
2026
Q1 		$229K Buy
55,222
+30,175
+120% +$122K ﹤0.01% 4818
2025
Q4 		$162K Buy
25,047
+8,472
+51% +$52.8K ﹤0.01% 4835
2025
Q3 		$92.7K Sell
16,575
-1,457
-8% -$6.3K ﹤0.01% 4758
2025
Q2 		$59.7K Buy
18,032
+1,000
+6% +$2.87K ﹤0.01% 5113
2025
Q1 		$49.4K Sell
17,032
-122,559
-88% -$371K ﹤0.01% 4642
2024
Q4 		$498K Buy
+139,591
New +$644K ﹤0.01% 3905

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Raymond James Financial's AQST Position: Q2 2026 in Review

Raymond James Financial reduced its Aquestive Therapeutics (AQST) stake by 9.5% in Q2 2026, selling an estimated $22K and leaving 49,988 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #5031.

Raymond James Financial first reported a position in AQST in Q4 2024 and has held it in 7 quarters since. The position peaked at $498K in Q4 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Raymond James Financial held 49,988 shares of Aquestive Therapeutics worth $208K as of Q2 2026.
  • Raymond James Financial sold 5,234 Aquestive Therapeutics shares in Q2 2026, an estimated $22K.
  • Aquestive Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5031 holding.
  • Raymond James Financial first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Aquestive Therapeutics position peaked at $498K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.